Evidence map›Paper›PMID 23954384›Full record

ArticleVaccine2013

SIV antigen-specific effects on immune responses induced by vaccination with DNA electroporation and plasmid IL-12.

Ross W Lindsay, Ian Ouellette, Heather E Arendt, Jennifer Martinez, Joanne DeStefano, Mary Lopez, George N Pavlakis, Maria J Chiuchiolo, Christopher L Parks, C Richter King

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ross W LindsayInternational AIDS Vaccine Initiative, 140 58th Street, Brooklyn, NY 11220, USA. Electronic address: rlindsay@iavi.org.
Ian Ouellette
Heather E Arendt
Jennifer Martinez
Joanne DeStefano
Mary Lopez
George N Pavlakis
Maria J Chiuchiolo
Christopher L Parks
C Richter King
International AIDS Vaccine Initiative · USNational Cancer Institute · US

Funding

Immunotherapeutic Approaches for AIDSZIABC010749 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$21.6M
Heterodimeric IL-15 in Cancer ImmunotherapyZIABC010750 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$15.6M
Intramural NIH HHS ZIA BC010750
6 · The paper itself

Abstract

Molecular adjuvants are important for augmenting or modulating immune responses induced by DNA vaccination. Promising results have been obtained using IL-12 expression plasmids in a variety of disease models including the SIV model of HIV infection. We used a mouse model to evaluate plasmid IL-12 (pIL-12) in a DNA prime, recombinant adenovirus serotype 5 (rAd5) boost regimen specifically to evaluate the effect of IL-12 expression on cellular and humoral immunity induced against both SIVmac239 Gag and Env antigens. Priming with electroporated (EP) DNA+pIL-12 resulted in a 2-4-fold enhanced frequency of Gag-specific CD4 T cells which was maintained through the end of the study irrespective of the pIL-12 dose, while memory Env-specific CD4+T cells were maintained only at the low dose of pIL-12. There was little positive effect of pIL-12 on the humoral response to Env, and in fact, high dose pIL-12 dramatically reduced SIV Env-specific IgG. Additionally, both doses of pIL-12 diminished the frequency of CD8 T-cells after DNA prime, although a rAd5 boost recovered CD8 responses regardless of the pIL-12 dose. In this prime-boost regimen, we have shown that a high dose pIL-12 can systemically reduce Env-specific humoral responses and CD4T cell frequency, but not Gag-specific CD4+ T cells. These data indicate that it is important to independently characterize individual SIV or HIV antigen immunogenicity in multi-antigenic vaccines as a function of adjuvant dose.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ViralAntigens, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesElectroporationImmunologic MemoryInterleukin-12MiceMice, Inbred C57BLSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeVaccinationVaccines, DNAAdjuvants, ImmunologicAntibodies, ViralAntigens, ViralInterleukin-12SAIDS VaccinesVaccines, DNAAdenovirusAntibodyDNAIL-12T cell

Identifiers

PMID23954384
PMCPMC7570371
OpenAlexW2060051337

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.